NEW YORK (GenomeWeb News) – Exact Sciences said today that it is undertaking a number of cost-reduction efforts, including laying off eight employees and suspending validation studies of its Version 2 stool-based technology for colorectal cancer screening, in an effort to conserve cash while “pursuing a strategic alternative for the business.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.